Radium-223 (Xofigo, Bay88-8223)
Sponsors
Bayer
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms, Castration-Resistant
Unknown Phase
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
CompletedNCT03563014
Start: 2018-07-31End: 2019-01-31Updated: 2020-05-20
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
CompletedNCT03896984
Start: 2019-03-18End: 2020-12-14Updated: 2021-12-29